Free Trial

SciSparc (SPRC) Stock Price, News & Analysis

-0.03 (-2.59%)
(As of 05/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
36,032 shs
Average Volume
95,161 shs
Market Capitalization
P/E Ratio
Dividend Yield
Price Target
SPRC stock logo

About SciSparc Stock (NASDAQ:SPRC)

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

SPRC Stock Price History

SPRC Stock News Headlines

SciSparc to acquire AutoMax in strategic merger
SciSparc Ltd: SciSparc to Acquire AutoMax
SciSparc to Acquire AutoMax
See More Headlines
Receive SPRC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SciSparc and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded


Pretax Margin


Sales & Book Value

Annual Sales
$2.88 million
Book Value
$13.57 per share


Free Float
Market Cap
Not Optionable
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Oz Adler CPA (Age 37)
    CEO & CFO
    Comp: $363k
  • Mr. Itschak Shrem (Age 77)
    President & Director
    Comp: $219k
  • Dr. Adi Zuloff-Shani Ph.D. (Age 55)
    Chief Technologies Officer
    Comp: $274k

SPRC Stock Analysis - Frequently Asked Questions

How have SPRC shares performed in 2024?

SciSparc's stock was trading at $4.88 at the beginning of the year. Since then, SPRC shares have decreased by 76.8% and is now trading at $1.13.
View the best growth stocks for 2024 here

When is SciSparc's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, July 1st 2024.
View our SPRC earnings forecast

When did SciSparc's stock split?

SciSparc's stock reverse split on the morning of Thursday, September 28th 2023. The 1-26 reverse split was announced on Thursday, September 28th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

How do I buy shares of SciSparc?

Shares of SPRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SPRC) was last updated on 5/26/2024 by Staff

From Our Partners